Submissions

Browse Submissions

Filter Results

CHPA charged IOM to develop a proposed framework for categorizing and prioritizing DS ingredients based on safety issues, describe a process for developing a system of scientific reviews for evaluating the safety of DS ingredients, and develop at least six scientific reviews as prototypes for the system.

Oct 11, 2001

Comments before the White House Commission on Complementary and Alternative Medicine Policy on information development and dissemination.

Mar 26, 2001

Oral testimony of the Consumer Healthcare Products Association to the White House Commission on Complementary and Alternative Medicine Policy.

Mar 16, 2001

Letter to Charles Ganley, M.D. regarding the agency's determination and comments pertaining to psyllium.

Oct 23, 2000

This submission represents CHPA's detailed written comments as follow-up to the June meeting and is intended to complement the Association's oral presentation.

Aug 25, 2000

Comments on the safety evaluation of ephedra at the public meeting on the safety of dietary supplements containing ephedrine alkaloids.

Aug 9, 2000

CHPA presentations at Food and Drug Administration OTC Part 15 hearing - Over-the-Counter Medications: A Success Story.

Jun 28, 2000

CHPA submits these comments on the proposal published by the Food and Drug Administration in 64 Fed. Reg. 66822 (November 30, 1999) to revise its citizen petition regulations, 21 C.F.R. § 10.25 and 21 C.F.R. § 10.30.

Feb 28, 2000

CHPA submits these written comments in response to FDA’s notice in the Federal Register concerning “Guidance for Industry: Significant Scientific Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplements.”

Feb 22, 2000

Enclosed for DA review is an "Update on Safety Studies with Benzoyl Peroxide" submitted by the NDMA Benzoyl Peroxide Study Group.

Feb 26, 1999

Filter Results